Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers (Q38307934)

2 September 2017

1 reference

title

Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers (English)

1 reference

2 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25560275%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Stephan Petersenn

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25560275%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

1 April 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25560275%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25560275%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

245-252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25560275%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25560275%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11102-014-0627-0

13 June 2020

exact match

0 references

cites work

The burden of Cushing's disease: clinical and health-related quality of life aspects

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Medical management of Cushing's disease: what is the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Update in the medical therapy of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Medical therapy of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Efficacy of medical treatment in Cushing's disease: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Treatment of Cushing's disease: a mechanistic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Medical treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

High variability in baseline urinary free cortisol values in patients with Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

The use of ketoconazole as an inhibitor of steroid production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Hepatic reactions associated with ketoconazole in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Fluconazole inhibits human adrenocortical steroidogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Long term control of hypercortisolism with fluconazole: case report and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Sustained Remission of Cushing's Disease with Mitotane and Pituitary Irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

The effect of o,p'-DDD on adrenal steroid replacement therapy requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Global clinical response in Cushing's syndrome patients treated with mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Mifepristone (RU 486) in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-014-0627-0

21 January 2018

1 reference

12 December 2020

Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring

1 reference

12 December 2020

Measurement of urinary free cortisol by current immunoassays: need for sex-dependent reference ranges to define hypercortisolism

1 reference

12 December 2020

Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole

1 reference

12 December 2020

Next Generation Medical Therapy for Cushing's Syndrome—Can We Measure a Benefit?

1 reference

12 December 2020

Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D and total serum calcium in hypercalcemic patients

1 reference

12 December 2020

Metyrapone in long-term management of Cushing's disease

1 reference

12 December 2020

Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review.

1 reference

12 December 2020

Ketoconazole in Cushing's disease: is it worth a try?

1 reference

12 December 2020

The medical treatment of Cushing's syndrome

1 reference

12 December 2020

Nizoral (Ketoconazole): drug safety communication- potentially fatal liver injury, risk of drug interactions, and adrenal gland problems

1 reference

12 December 2020

Inhibition of corticosteroid secretion by amphenone in a patient with adrenocortical carcinoma

1 reference

12 December 2020

Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

1 reference

12 December 2020

Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases

1 reference

12 December 2020

10.1007/S11102-014-0627-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25560275%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference